Senzime AB (SE:SEZI)
:SEZI
Want to see SE:SEZI full AI Analyst Report?
SEZI Stock Chart & Stats
kr5.13
-kr0.14(-2.60%)
At close: 4:00 PM EST
kr5.13
-kr0.14(-2.60%)
Day’s Range― - ―
52-Week Rangekr3.85 - kr7.38
Previous CloseN/A
Volume45.51K
Average Volume (3M)534.13K
Market Cap
kr731.05M
Enterprise Valuekr697.49M
Total Cash (Recent Filing)kr55.35M
Total Debt (Recent Filing)kr21.79M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding157,215,040
10 Day Avg. Volume328,516
30 Day Avg. Volume534,125
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr176.30M
Bulls Say, Bears Say
Bulls Say
Recurring Sensor RevenueHigh and growing disposable sensor volumes create predictable, per‑patient recurring revenue that scales with installed base. Because sensors are the majority of revenues and have higher incremental margins than capital sales, continued sensor adoption supports durable revenue visibility and margin leverage as installations grow.
Strong Underlying Gross MarginsA ~69% underlying gross margin indicates robust product economics. As sensor volumes and service models (e.g., TetraGraph‑as‑a‑Service) scale, a large portion of incremental revenue should flow to operating leverage, supporting sustainable margin expansion and a clear path toward profitability if sales continue to grow.
Conservative Balance Sheet And RunwayLow leverage and material equity provide financial flexibility while the business scales. Combined with reported cash and an available credit facility, the conservative capital structure reduces near‑term solvency risk and gives management time to execute commercialization, regulatory rollouts, and margin initiatives without immediate funding pressure.
Bears Say
High Cash BurnSustained large negative operating and free cash flows deplete balance‑sheet resources and create reliance on external financing or equity raises. Until operating cash flow turns positive, the company faces dilution risk and constrained ability to invest in sales, regulatory work, or R&D, making execution critical.
Negative Profitability And Recent Revenue DeclineDeep negative margins and a recent revenue contraction indicate the business has not yet achieved scale to cover its fixed cost base. Continued losses will erode returns on equity and limit reinvestment capacity; durable recovery requires sustained top‑line growth and further cost discipline to realign economics.
Commercial & Regulatory Execution RiskHospitals and IDNs have long procurement cycles, clinician adoption hurdles and region‑specific regulatory timing that can delay monitor installations and recurring sensor revenue. Such execution and regulatory delays make achievement of cash‑flow and growth targets contingent on faster deal closures and approvals.
Senzime AB News
SEZI FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was kr3.85 and its highest was kr7.38 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is kr731.05M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Aug 21, 2026 which is in 113 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Apr 22, 2026. The company reported -kr0.143 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.143.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -kr0.143 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.901%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SE:SEZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
SEZI Company Deck
SEZI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook: the company reported strong underlying operational momentum (notably sensor growth, a 1M monitored‑patient milestone, margin improvement, new business models like TetraGraph‑as‑a‑Service, TetraCom and important customer wins) while acknowledging a temporary Q1 growth dip driven by delayed U.S. deals, FX and tariff headwinds and some regional regulatory timing issues. Management emphasizes cost discipline, a solid pipeline, available funding and confidence in meeting full‑year objectives, but execution (recovering delayed deals, FX/tariff resolution and regulatory rollouts) is needed to realize targets.View all SE:SEZI earnings summariesTechnical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Integrum AB Class B
―
Sedana Medical AB
―
OssDsign AB
―
Options Prices
Currently, No data available
---